Christine Lovly, MD, PhD, joins LUNGevity's Scientific Advisory BoardDr. Christine Lovly, associate professor of medicine at Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center as well as co-leader of the Translational Research and Interventional Oncology Program at Vanderbilt-Ingram Cancer Center, has joined LUNGevity’s Scientific Advisory Board. Dr. Lovly is also a former LUNGevity Career Development Awardee, whose research focuses on understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer. LUNGevity’s Scientific Advisory Board is a group of 25 world-renowned scientists and researchers who guide LUNGevity’s research program. In addition to overseeing the Foundation’s translational research strategy and program, they help ensure LUNGevity is tackling the most important issues that those affected by lung cancer face, from clinical trial access to ensuring to patients receive optimal care. New patient education materials availableCheck out our new education materials on radiation therapy to understand how it works, what radiation therapy options are currently available, ways that radiation therapy side effects can be managed, and whether radiation therapy might be a good treatment option for you. Available in both a trifold brochure and a booklet, these and other educational materials can be downloaded on the LUNGevity website. Addressing questions about lung cancer clinical trials during COVID-19We have heard many concerns from our community about how the public health crisis might be affecting patients’ clinical trials. Clinical trials are incredibly important to our community because many times they can be the best treatment option. LUNGevity hosted a listening session with the FDA Oncology Center of Excellence and the FDA thoracic oncology team to discuss the impact of the COVID-19 pandemic on lung cancer clinical trials and address some of these questions, such as:
It was an informative session and included input from four lung cancer survivors. We encourage you to watch the video and download the questions and answers from the session if you have questions or concerns about clinical trials and drug development during the COVID-19 pandemic. This video is part of an ongoing series on our COVID-19 and Lung Cancer online resource, Conversations with Healthcare Experts, helping patients navigate lung cancer during this public health emergency. Join our virtual meetups!Every Friday, LUNGevity hosts multiple, small-group virtual Zoom meetups with patients and survivors who want to meet and connect with others like them. These meetings are capped at 10-12 people so you won’t feel lost in the crowd. Join us for virtual support, information, and friendship with your peers impacted by lung cancer! Learn more and sign up on our website. We need your feedback!Do you (or does a loved one) have non-small cell lung cancer (NSCLC)? We are seeking your feedback on your biomarker testing experience. By participating in this 30-minute survey, YOU could help shape how we address gaps in the biomarker testing experience for ALL lung cancer patients regardless of their race, ethnicity, geographic location, and socioeconomic status. LUNGevity events go virtual!Join LUNGevity for our first-ever nationwide walk Breathe Deep TOGETHER on Saturday, May 30! No matter where you live, you can join us the morning of May 30 for a virtual broadcast of celebration, hope, and remembrance followed by a walk in your own neighborhood; there will even be a yoga warm-up to kick off our national walk. The event has lots of fun new features, so be sure to check out the event website to learn more and register—it’s free! Together, we can make this the biggest Breathe Deep event ever! We have more exciting events in the works. Stay tuned, stay committed, and stay positive! Quick links
|